Le Lézard
Classified in: Health
Subject: SVY

Amyotrophic lateral sclerosis (ALS) -Epidemiology Forecast to 2025


NEW YORK, Nov. 17, 2017 /PRNewswire/ --

DelveInsight "Amyotrophic lateral sclerosis (ALS) - Epidemiology Forecast To 2025" provides an overview of the epidemiology trends of Amyotrophic lateral sclerosis (ALS) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan).



Read the full report: https://www.reportlinker.com/p05144675



It includes 10 years epidemiology historical and forecasted data of Amyotrophic lateral sclerosis (ALS) prevalent or incident cases segmented by age, sex and subpopulations. The Report also discusses the prevailing risk factors, disease burden with special emphasis on the unmet medical need associated with the Amyotrophic lateral sclerosis (ALS). The report is built using data and information sourced from proprietary databases, primary and secondary research and in-house Forecast model analysis by DelveInsight team of industry experts.

Scope of the Report
The Report includes the prevalent population and how will it change over the next eight years.
Prevalent or incident cases segmented by age and sex.
Coverage of key Amyotrophic lateral sclerosis (ALS) subpopulations and its prevalent or incident cases
The key differences in epidemiology patterns across the seven market segments

Key Coverage and Benefits
The report will help in developing business strategies by understanding the trends shaping and driving the global Amyotrophic lateral sclerosis (ALS) market.
Identifying prevalent patient populations as well as risk factors in the global Amyotrophic lateral sclerosis (ALS) market will help to improve product design, pricing, and launch plans.
Organize sales and marketing efforts by identifying the best opportunities for Amyotrophic lateral sclerosis (ALS) therapeutics in each of the markets covered.

Read the full report: https://www.reportlinker.com/p05144675

About Reportlinker
ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

 

SOURCE Reportlinker


These press releases may also interest you

at 07:35
Endeavor BioMedicines, Inc. ("Endeavor"), a clinical-stage biotechnology company developing medicines with the potential to deliver transformational clinical benefits to patients with life-threatening diseases, today announced the closing of a $132.5...

at 07:30
BioArctic AB's (publ) partner Eisai today published the preliminary global revenue for Leqembi during the first quarter 2024, in conjunction with their partner Biogen's first quarter report. In total, sales of JPY 2.83 billion were recorded in the...

at 07:25
RxLightning, creator of the industry's leading platform for streamlining specialty medication access and affordability, is proud to have reached a number of meaningful milestones in the last year ? including significant increases in provider users,...

at 07:12
Highlights from Chiesi Group's 2023 financial report: Sales increased to over ?3 billion, up 10% compared to 2022 (+12% @CER), driven by the Rare business unit growth (65% @CER), and steady growth of all products in all its Regions24% of 2023 sales...

at 07:05
Av?sis and Harmony Health have joined forces to bridge oral healthcare gaps for underserved Medicaid populations with special healthcare needs. The pilot aims to revolutionize preventive dentistry by harnessing the power of real-time salivary testing...

at 07:05
United Therapeutics Corporation , announced today that it will report its first quarter 2024 financial results before the market opens on Wednesday, May 1, 2024. A press release detailing the quarterly results will be issued that day at approximately...



News published on and distributed by: